Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. (GLMD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
glmd · stock forecast · 16 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 16 Wall Street analysts in the past 3 months
Buy
16 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.47
Short-Term Price Prediction
Short-term predictions are paused during the ±3-day earnings window to avoid unreliable signals.
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GLMD · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-04-04 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2023-07-24 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2022-08-08 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2022-08-08 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2022-05-18 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2022-05-03 | Raymond James | Maintains | Outperform→Outperform |
| 2022-05-03 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2021-05-17 | Canaccord Genuity | Maintains | Buy→Buy |
| 2021-03-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-01-08 | Raymond James | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Galmed Pharmaceuticals Ltd. (GLMD) stock. Of the recent 32 rating actions, 2 were upgrades and 8 were downgrades. 16 analysts currently cover GLMD.
Analyst Recommendation Trends
GLMD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$6M
↑ 14.3% YoY
Revenue Next Year
$6M
↑ 1.4% YoY
EPS This Year
$-1.56
EPS Next Year
$-0.90
↓ 42.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast GLMD EPS of $-1.56 for the current fiscal year, based on estimates from 1 analysts. The GLMD revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GLMD stock forecast is supported by two independent data sources: analyst consensus ratings from 16 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GLMD price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GLMD stock price prediction for 2027 estimates an average of $0. The GLMD stock prediction for 2030 projects a range of $0–$0.
Galmed Pharmaceuticals Ltd. trades on NASDAQ under the ticker GLMD. The GLMD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
GLMD forecast · 8 questionsAccording to 16 Wall Street analysts, the average 12-month GLMD price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.47.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.